Catalog No.
YHK48701
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ser86-Val582
Predicted molecular weight
58.15 kDa
Nature
Recombinant
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q9UQ13
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% SKL, 1mM EDTA, 5% Trehalose, 2% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Leucine-rich repeat protein SHOC-2, KIAA0862, Protein sur-8 homolog, Protein soc-2 homolog, SHOC2
Note
For research use only.
Genotype-cardiac phenotype correlations in a large single-center cohort of patients affected by RASopathies: Clinical implications and literature review., PMID:34643321
Shoc2 recognizes bacterial flagellin and mediates antibacterial Erk/Stat signaling in an invertebrate., PMID:35073369
Genetic screening of early-onset patients with systemic lupus erythematosus by a targeted next-generation sequencing gene panel., PMID:35086391
Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors., PMID:35091470
Polycistronic baculovirus expression of SUGT1 enables high-yield production of recombinant leucine-rich repeat proteins and protein complexes., PMID:35131438
Two Japanese patients with Noonan syndrome-like disorder with loose anagen hair 2., PMID:35338599
Expanding the molecular spectrum of pathogenic SHOC2 variants underlying Mazzanti syndrome., PMID:35348676
Structural basis for SHOC2 modulation of RAS signalling., PMID:35768504
The Clinical and Molecular Assessment of Iranian Families with Severe Congenital Neutropenia, Identification of HYOU1 and SHOC2 as Potential Novel Gene Defects., PMID:35822684
Structure of the MRAS-SHOC2-PP1C phosphatase complex., PMID:35830882
Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex., PMID:35831509
Structure of SHOC2-PP1C-RAS Reveals a Mechanism of RAF Activation., PMID:35838404
Molecular and clinical profile of patients referred as Noonan or Noonan-like syndrome in Greece: a cohort of 86 patients., PMID:35904599
Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome., PMID:36175670
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition., PMID:36198031
Shoc2 controls ERK1/2-driven neural crest development by balancing components of the extracellular matrix., PMID:36265687
RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations., PMID:36304179
lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis., PMID:36420706
The Sag-Shoc2 axis regulates conversion of mPanINs to cystic lesions in Kras pancreatic tumor model., PMID:36543126
New insights on Noonan syndrome's clinical phenotype: a single center retrospective study., PMID:36566191
Structural insights into the role of SHOC2-MRAS-PP1C complex in RAF activation., PMID:37074066
LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis., PMID:37166421
SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus., PMID:37170083
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS., PMID:37277529
Lipid profile in Noonan syndrome and related disorders: trend by age, sex and genotype., PMID:37588986
Aberrant N-myristoylation as a prelude to autoimmune manifestations in patients with SHOC2 mutations., PMID:37793491
M-type phospholipase A2 receptor-associated membranous nephropathy in a patient with Noonan-like syndrome with loose anagen hair., PMID:37817399
High frequency of hotspot mutation in PTPN11 gene among Moroccan patients with Noonan syndrome., PMID:37987971
Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy., PMID:37996408
Co-Occurring Thrombotic Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia in a Child Carrying the Pathogenic SHOC2 c.4A>G (p.Ser2Gly) Variant., PMID:38019730
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)., PMID:38072173
The expression of congenital Shoc2 variants induces AKT-dependent feedback activation of the ERK1/2 pathway., PMID:38187642
circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop., PMID:38219533
Signaling from RAS to RAF: The Molecules and Their Mechanisms., PMID:38316136
Exploiting Bacterial Effector Proteins to Uncover Evolutionarily Conserved Antiviral Host Machinery., PMID:38352400
Mapping dynamic molecular changes in hippocampal subregions after traumatic brain injury through spatial proteomics., PMID:38735925
Exploiting bacterial effector proteins to uncover evolutionarily conserved antiviral host machinery., PMID:38753575
The expression of congenital Shoc2 variants induces AKT-dependent crosstalk activation of the ERK1/2 pathway., PMID:38881369
RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations., PMID:38882927
Human Genetics of Ventricular Septal Defect., PMID:38884729
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance., PMID:39103541
Noonan syndrome and Noonan-like syndrome with loose anagen hair: rare phenotypes may emerge during follow-up., PMID:39144424
Crystal structure of the GDP-bound human M-RAS protein in two crystal forms., PMID:39196705
Small-molecule targeting BCAT1-mediated BCAA metabolism inhibits the activation of SHOC2-RAS-ERK to induce apoptosis of Triple-negative breast cancer cells., PMID:39490614
The small GTPase MRAS is a broken switch., PMID:39809765
SHOC2 plays an oncogenic or tumor-suppressive role by differentially targeting the MAPK and mTORC1 signals in liver cancer., PMID:39871893
Ras-MAPK pathway in patients with lupus nephritis., PMID:40102014
Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy., PMID:40131150
Signaling scaffold Shoc2 regulates lymphangiogenesis by suppressing mTORC1-mediated IFN responses., PMID:40196569
Targeting the SHOC2-RAS interaction in RAS-mutant cancers., PMID:40335703
For research use only. Not for human or drug use.
